October 26, 2016 8:00 PM ET


Company Overview of Angiochem Inc.

Company Overview

Angiochem Inc., a clinical-stage biotechnology company, engages in discovering and developing peptide drug conjugates for the treatment of neurological diseases. The company focuses on developing small molecules and biologics for the treatment of a range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases, pain, and other diseases. It develops ANG1005, a taxane derivative that leverages low density lipoprotein receptor-related protein 1 (LRP-1) to cross the blood-brain barrier (BBB) and enter cancer cells; peptide antibody conjugates; ANG4043, an anticancer therapy to treat breast cancer metastases in the brain; antibody-drug conjugates that cross th...

201 President-Kennedy Avenue

Suite PK-R220

Montreal, QC H2X 3Y7


Founded in 2003





Key Executives for Angiochem Inc.

Executive Chairman
Age: 52
Head of Finance
Vice President of Development
Compensation as of Fiscal Year 2016.

Angiochem Inc. Key Developments

Angiochem's ANG1005 Shows Clinical Benefits and Prolonged Survival for Breast Cancer Patients with Brain Metastases

Angiochem presented data from its Phase II trial for its lead compound, ANG1005. In this report of the multi-center, open label Phase II trial ANG1005-CLN-04, ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases. The data on those patients enrolled in ANG1005-CLN-04 who had leptomeningeal carcinomatosis (LC) as well as recurrent breast cancer brain metastasis was updated at the 12th EANO Meeting, Mannheim, Germany.

Angiochem Announces Successful End-Of-Phase 2 Meeting with FDA for ANG1005

Angiochem announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for ANG1005. As a result, the company is in final preparation stages to commence its Phase 3 trial to support a New Drug Application (NDA) for ANG1005 in patients with leptomeningeal carcinomatosis (LC) from breast cancer. The trial design for the single pivotal study is a randomized two-arm superiority trial in breast cancer patients with recurrent brain metastases (BCBM patients) and LC. The primary efficacy endpoint of the study is a significant improvement in overall survival with ANG1005 compared to treatment with Physicians' Best Choice. ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated BCBM patients with LC in the company's Phase 2 trial.

Angiochem Announces Executive Appointments

Angiochem appointed Mr. John Huss as Executive Chairman and elected a new board of directors. John Huss has more than 25 years of global pharmaceutical experience. He spent 20 years with Merck & Co., Roche and Sanofi on the pharmaceutical side of the business, before moving to biotechnology. He served as CEO, President and Director of Theratechnologies and is currently Founder, President and CEO of H&P Labs Inc. He is also Vice-President, member of the Executive Committee and a Director at BioQuebec. The board also appointed Robert Blain as a board of director. Robert Blain, with more than 20 years in the international entertainment industry, is Co-CEO of Groupe Lune Rouge Inc. As well as taking care of the Family office of Mr. Guy Laliberte, Mr. Blain also acts as an investment manager in Lune Rouge. Since 2007, Mr. Blain has been an administrator and treasurer for One Drop Foundation which aims to fight poverty by supporting access to water worldwide. He also sits as the Treasurer on Sainte-Justine UHC Foundation, one of the most important pediatric centers in North America.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Angiochem Inc., please visit www.angiochem.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.